SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Denbury Inc. (DEN) trades at a trailing P/E of 10.0. Trailing earnings yield is 9.96%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (64/100, Pass) — P/E is below market average (10.0); PEG ≤ 1.0 — Peter Lynch undervalued (0.01); earnings yield beats bond yields (9.96%).
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 9.96% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
- Analyst consensus target $88.33 (-0.4% downside) — slight downside risk — the market may be ahead of analyst expectations.
Overall SharesGrow Score: 70/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
64/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — DEN
Valuation Multiples
P/E (TTM)10.0
Forward P/EN/A
PEG Ratio0.01
Forward PEGN/A
P/B Ratio0.00
P/S Ratio2.83
EV/EBITDA0.0
Per Share Data
EPS (TTM)$8.83
Book Value / Share$0.00
Revenue / Share$31.36
FCF / Share$0.00
Yields & Fair Value
Earnings Yield9.96%
Dividend Yield0.00%
Analyst Target$88.33 (-0.4%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$1.11 |
$2.49B |
$409.6M |
16.4% |
| 2014 |
$1.81 |
$2.42B |
$635.49M |
26.3% |
| 2015 |
$-12.57 |
$1.24B |
$-4.39B |
-352.6% |
| 2016 |
$-2.61 |
$960.57M |
$-976.18M |
-101.6% |
| 2017 |
$0.41 |
$1.12B |
$163.15M |
14.6% |
| 2018 |
$0.71 |
$1.45B |
$322.7M |
22.2% |
| 2019 |
$0.45 |
$1.26B |
$216.96M |
17.2% |
| 2020 |
$-3.90 |
$714.16M |
$-1.49B |
-208.1% |
| 2021 |
$1.04 |
$1.24B |
$56M |
4.5% |
| 2022 |
$8.83 |
$1.7B |
$480.16M |
28.2% |
